Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
SELLAS Life Sciences Group (SLS) Gets a Buy Rating from Maxim Group
04:02pm, Thursday, 19'th Mar 2020
Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group (SLS) today and set a price target of $8.00. The company's shares
SELLAS Life Sciences Group (SLS) Gets a Buy Rating from Maxim Group
04:02pm, Thursday, 19'th Mar 2020
Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group (SLS – Research Report) today and
Actinium Treats First Patient in AML Study on Actimab-A Combo
12:00am, Friday, 06'th Mar 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial. Th
Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
12:33pm, Wednesday, 26'th Feb 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in
Actinium Announces Actimab-A Plus 7+3 Combination Trial For Newly Diagnosed Acute Myeloid Leukemia Patients
12:00am, Wednesday, 26'th Feb 2020Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
12:00am, Tuesday, 25'th Feb 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN), Beyondspring (BYSI) and Agenus (AGEN).
Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN – Research
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today findings from the SIERRA trial that were presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT an
William Blair Reiterates a Buy Rating on Seattle Genetics (SGEN)
07:28pm, Friday, 14'th Feb 2020
In a report issued on February 11, Andy Hsieh from William Blair reiterated a Buy rating on Seattle Genetics (SGEN). The company's shares closed last
William Blair Reiterates a Buy Rating on Seattle Genetics (SGEN)
07:27pm, Friday, 14'th Feb 2020
In a report issued on February 11, Andy Hsieh from William Blair reiterated a Buy rating on Seattle Genetics (SGEN
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at the 2020 Transplant
